Hemophagocytic lymphohistiocytosis in 2 patients with underlying IFN-g receptor deficiency
To the Editor:
Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory disorder, caused by mutations in genes required for lymphocyte cytotoxicity or may be secondary to infections, malignancy, and autoimmunity. 1, 2 Animal models have indicated a central role for IFN-g produced by CD8
1 T cells in the pathophysiology of HLH, 3 and a possible clinical efficacy of anti-IFN-g antibody therapy for the control of HLH. 4 Here, we detail 2 unrelated cases of fatal IFN-g receptor (IFNgR) deficiency with mycobacterial infections who were initially diagnosed with HLH. Patient A, a 2-month-old girl, and patient B, a 4-year-old girl (see Case Reports and Fig E1, A and B, in this article's Online Repository at www.jacionline.org), fulfilled, respectively, 7 of 8 and 5 of 6 HLH diagnostic criteria 1 (see Table E1 in this article's Online Repository at www.jacionline.org).
For information on methods, see this article's Online Repository at www.jacionline.org.
In patient A, cytotoxic lymphocyte function was evaluated twice with the consistent finding of pathologically low natural killer (NK)-cell cytotoxic function, even after IL-2 stimulation (see Fig E2, A and B, in this article's Online Repository at www. jacionline.org). This reflected low NK cell numbers (Fig 1, A) , possibly caused by antithymocyte globulin treatment. NK-cell cytotoxic activity was not evaluated in patient B because of the very low frequency of peripheral blood NK cells, already present at admission (Fig 1, B) . In both patients, additional characterization of NK-cell and T-cell function did not reveal defects consistent with primary HLH caused by an impairment in lymphocyte cytotoxicity (Fig 1, C-F ; also see Fig E2, C and D) . Accordingly, no mutations were found in known HLH-associated genes. After the diagnosis of HLH, the patients were found positive for cytomegalovirus and Mycobacterium bovis infections, and for EBV and Mycobacterium tuberculosis (MTB) infections, respectively. Moreover, in patient B, plasma IFN-g levels were constitutively elevated, without increasing further on stimulation with mitogen or MTB antigen (see Fig E3, A and B in this article's Online Repository at www.jacionline.org). In light of a disseminated mycobacterial infection, a differential diagnosis of Mendelian susceptibility to mycobacterial disease (MSMD) was considered, although fulminant HLH in the context of defective IFN-g signaling was deemed unlikely.
In patient A, Sanger sequencing of IFNGR1 and IFNGR2 was followed by whole exome sequencing. Variant calling did not identify mutations able to explain the phenotype. Only a homozygous missense variant in FANCA (p.H1417D), described in patients with Fanconi anemia, was found. Instead, analysis of copy number variation revealed a possible homozygous deletion of exon 2 of IFNGR2 (Fig 2, A) . Of note, exon 2 was not amplified by PCR. On evaluation of IFNGR2 transcripts, the patient expressed only a truncated IFNGR2 transcript lacking exon 2 (c.74_216del, p.Asp25Alafs*38; Fig 2, B and C) . In patient B, sequencing of IFNGR1 and IFNGR2 revealed a homozygous IFNGR1 c.655G>A (p.G219R) missense variant, affecting a conserved residue in the second domain of the extracellular region of IFN-gR1. The parents and the healthy sister were heterozygous carriers (Fig 2, D) . The G219R variant was predicted damaging and was not found in the 1000 Genomes database and in 150 healthy Chinese individuals. An in-frame deletion affecting residue 218 of IFN-gR1 was described in a patient with MSMD carrying compound heterozygous IFNGR1 mutations (the other mutation being p.V61Q), resulting in normal IFN-gR1 surface expression but severely impaired IFN-g binding. 5 The G219R mutation may have a similar effect. With mycobacterial infections and mutations in IFNGR1 or IFNGR2, the patients fulfilled a diagnosis of MSMD in addition to HLH. A molecular defect in either chain of the IFN-gR heterodimer impairs signaling and causes increased susceptibility to severe Mycobacterium species infections. 6 After IFN-g stimulation, no signal transducer and activator of transcription 1 phosphorylation was observed by flow cytometry in monocytes from patient A (Fig  2, E) , establishing a diagnosis of complete IFN-gR deficiency. In patient B, it is not clear whether the IFN-gR1 G219R mutation causes complete or partial IFN-gR1 deficiency because such data were not available. Nonetheless, the high levels of IFN-g found in patient B may suggest a complete deficiency. Both the identified genetic aberrations were novel. Importantly, this represents the first report of HLH in patients with genetic aberrations impairing IFN-g signaling. Because IFN-g is considered a cardinal cytokine in the development of HLH, a link between HLH and defects in IFN-g signaling is surprising. Mouse models indicate a crucial role of IFN-g for the development of primary HLH. 3 Fatal HLH-like disease in Prf1 knockout mice infected with lymphocytic choriomeningitis virus can be treated by antibody-mediated IFN-g neutralization. 3 Intriguingly, antibody-mediated TNF neutralization ameliorated organ damage in Prf1 knockout mice challenged with murine cytomegalovirus. 7 Moreover, in wild-type mice, high levels of IL-4 or repeated Toll-like receptor 9 (TLR9) stimulation can induce the development of an HLH-like or macrophage activation syndrome-like disease. 8, 9 On TLR9 stimulation, IFN-g-knockout mice developed macrophage activation syndrome-like disease with a severity comparable to that of wild-type mice, suggesting that immune pathology may arise independent of IFN-g. 9 This model may provide an explanation for HLH in our patients. DNA from M tuberculosis is a potent stimulus for TLR9-dependent responses. 10 We speculate that genetic susceptibility to severe and sustained mycobacterial infection may predispose to strong TLR stimulation, resulting in HLH. The low NK cell numbers in our patient may have also enhanced the risk of developing HLH.
Interestingly, hemophagocytosis was not found in both cases. Hemophagocytosis is often viewed as a late symptom and is not required for a diagnosis of HLH. 1 In mice, infusion of IFN-g can induce hemophagocytosis by macrophages.
11 Notably, such macrophage-mediated macropinocytosis depends on IFN-gR signaling in macrophages.
11 Therefore, our patients may further support a role for IFN-gR signaling in driving hemophagocytosis, but not other pathologic features of the HLH syndrome.
Based on experiments in animal models, a clinical efficacy of anti-IFN-g antibody treatment in patients with primary HLH has been proposed. 3, 4 Clinical trials are ongoing, notably with active infections, including mycobacterial, representing exclusion criteria. Our findings suggest that other cytokines, for example, TNF, may be important drivers of immune pathogenesis. In patients infected by multiple pathogens, blocking IFN-g may accommodate other infections, leading to TLR stimulation and HLH. Therefore, at least in settings of HLH associated with primary defects in immune function other than lymphocyte cytotoxicity, immune suppression besides anti-IFN-g antibody should be considered. It is noteworthy that antithymocyte globulin controlled HLH in both patients.
In conclusion, we report 2 cases of HLH in children with novel IFN-gR mutations. Importantly, our results highlight the significance of IFN-g-independent mechanisms in the immune pathology of HLH, provide new views on pathogenic mechanisms of human hyperinflammatory syndromes, and expand the spectrum of genetic conditions conferring susceptibility to HLH. Clinically, because different mechanisms seem to be involved in HLH pathogenesis, novel therapies, beside anti-IFN-g therapy, should be investigated. Defective natural killer-cell cytotoxic activity in NFKB2-mutated CVID-like disease
To the Editor:
Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency characterized by low immunoglobulin serum levels, low vaccine responses, and recurrent infections. The clinical presentation of CVID comprises a variable mixture of recurrent infections, autoimmune phenomena, granulomatous disease, and lymphoproliferation. The underlying genetic mechanisms have been elucidated in the last few years in less than 10% to 15% of the cases and involve mutations in CD19, MS4A1 (CD20), CR2 (CD21), ICOS, TNFRSF13C, TNFRSF13B, PLCG2 (phospholipase Cg2), CD81, LRBA, and PRKCD (protein kinase Cd). [1] [2] [3] Recently, germline heterozygous mutations in NFKB2 were identified in 10 patients to be associated with early-onset CVID with autoimmunity in most cases, 4,5 profound B-cell deficiency, 6 or a CVID-like phenotype. 7 All affected patients had hypogammaglobulinemia with variable association of the following clinical and immunologic features: central adrenal insufficiency (ACTH insufficiency), alopecia totalis or areata, trachyonychia, variable natural killer (NK) cell numbers, and defects in peripheral T and B cells. We report on a male patient with early-onset CVID who carried the heteroyzgous p.Arg853* mutation in NFKB2 and later developed central adrenal insufficiency (ACTH insufficiency), alopecia totalis, and trachyonychia. An extensive immunologic work-up was performed that, besides confirming the presence of T-and B-cell defects, revealed, as a novel finding, impaired NK-cell cytotoxic activity in vitro, despite normal NK cell counts.
The index patient was born to Italian nonrelated parents. Routine laboratory investigation was performed at age 15 months for growth delay and showed profound hypogammaglobulinemia -IgG, 95 mg/dL (normal values for age, 264-1509 mg/dL); IgA, less than 5 mg/dL (normal values for age, 17-178 mg/dL); IgM, less than 5 mg/dL (normal values for age, 48-337 mg/dL)-in the presence of normal peripheral B-cell counts (CD19 1 , 16.5%). Immunoglobulin replacement treatment was initiated. During follow-up, the patient presented with occasional infections of the upper respiratory tract. He developed alopecia totalis at the age of 4 years, followed by the development of trachyonychia. Endocrinological evaluation following a hypoglycemic episode (blood glycemic level, 26 mg/dL) revealed ACTH and cortisol insufficiency for which he was placed on replacement treatment with hydrocortisone. During adolescence, he developed hypothyroidism and required hormone replacement therapy. On the identification of hypogammaglobulinemia, a more extensive immunologic work-up revealed abnormalities of both T and B cells, namely, an accumulation of T cells in the early stages of differentiation with reduction of the terminal stages of T-cell development, for both CD4 and CD8 subsets, and the typical peripheral B-cell block of CVID with reduction in memory B cells, both switched and IgM memory ones, and lack of plasma cells (Table I) . Proliferative responses to mitogens were normal (Table I) .
On the description of NFKB2 mutations associated with early-onset CVID, ACTH insufficiency, alopecia totalis, and trachyonichia, 4,5 direct gene sequencing for NFKB2 was performed for the index patient. A c.2557C>T substitution was found, leading to the non-sense mutation p.Arg853* (Fig 1) . This is a de novo mutation because the patient's parents were wild type for this mutation. Interestingly, all patients described so far to be mutated in NFKB2, with the exception of 3 family members carrying a missense mutation, 6 carry de novo mutations. 4, 5, 7 The p.Arg853* mutation is disease-causing and was identified in the first description of NFKB2 mutations in CVID. 4 The index patient here described is the 11th patient to be affected with this genetic defect and the second one to carry the p.Arg853* mutation. Interestingly, the index patient is the first patient with germline NFKB2 mutation to develop clinically relevant hypothyroidism, underlying the clinical heterogeneity of this disorder. By reviewing the clinical data of the reported patients, [4] [5] [6] [7] it is evident that some clinical features are common to all patients, whereas others are sporadic (see Table E1 in this article's Online Repository at www.jacionline.org). Furthermore, the clinical and immunologic phenotype appears more severe in the presence of non-sense 4, 5, 7 rather than missense 6 mutations in NFKB2. Mutations in nuclear factor kappa B (NF-kB) essential PMA, Phorbol 12-myristate 13-acetate; RBE, recent bone marrow emigrants; RTE, recent thymic emigrants; TCR, T-cell receptor.
CASE REPORTS
Patient A, a 2-month-old girl, born to consanguineous Portuguese parents (Fig E1, A) , was initially admitted for impetiginized atopic eczema treated with flucloxacilin, which triggered an episode resembling a drug reaction with eosinophilia and systemic symptoms syndrome. Subsequently, she developed worsening fever, hepatosplenomegaly with cholestatic hepatitis, hyperferritinemia, hypofibrinogenemia, as well as thrombocytopenia, anemia, and elevated sCD25 level (Table E1) . Hemophagocytosis was not evident in bone marrow, liver, or skin. The patient fulfilled 7 of 8 HLH diagnostic criteria, E1 establishing a diagnosis of HLH (Table E1) . HLH treatment was initiated with dexamethasone, antithymocyte globulin, and cyclosporine, resulting in partial control of disease. Subsequently, the patient was found positive for cytomegalovirus (>10,000,000 viral copies/mL) and for Mycobacterium bovis in bone marrow and hepatic culture. Despite treatment for the infections, the clinical conditions worsened and the patient developed acute respiratory distress syndrome with fatal outcome at the age of 4.5 months.
Patient B, a 4-year-old girl, was born in Italy to apparently nonconsanguineous Chinese parents (Fig E1, B) . The patient was admitted for persistent fever, leucocytosis, and a mediastinal mass. She subsequently developed hepatosplenomegaly, anemia, neutropenia, thrombocytopenia, hypertriglyceridemia, and hyperferritinemia. Bone marrow aspirate, performed twice, did not show hemophagocytosis. However, the patient fulfilled 5 of 6 HLH diagnostic criteria examined (Table  E1 ). The patient was positive for EBV infection (180,000 viral copies/mL), while tuberculin skin and Quantiferon-TB test results were, respectively, negative and indeterminate. Interestingly, plasma IFN-g levels were constitutively high, without further increase in response to mitogen or TB-antigen stimulation ( Fig E3, A and B) . Dexamethasone, anti-CD20, and cyclophosphamide and gancyclovir were administrated, leading to partial remission of HLH and infection control. Two weeks later, the patient reactivated (with ferritin up to 395,644 ng/mL) and developed life-threatening conditions. Rabbit antithymocyte globulin was administered with sudden improvement, albeit persistent fever and the onset of ocular and neurologic symptoms. At this point, disseminated infection by M tuberculosis was diagnosed by PCR and cultures of blood, cerebral spinal fluid, and eye swab. A 5-drug antitubercular therapy was started with transient control followed by death from multiorgan failure.
METHODS
The studies were approved by the Regional Ethical Review Board in Stockholm, Sweden, and by the Regional Committee in Florence, Italy.
Genetic analyses
Genomic DNA was isolated from peripheral blood according to a standard procedure. Informed consent was obtained from the patients and their relatives. Genes responsible for familial HLH, IFNGR1, and IFNGR2 were analyzed by direct sequencing. For patient A, whole exome sequencing was performed on a HiSeq2000 Illumina machine. Agilent SureSelect v51UTRs kit was used for target enrichment. The sequencing reads were aligned to the human genome build37 (hg19) using BWA/0.7.4.
E2 Unified Genotyper GATK (v.2.5) E3 and Annovar software (version 2013Jun21) E4 were used for variant calling and annotation, respectively. Copy number variations were analyzed with the R package ExomeDepth. E5 RNA was isolated from blood or fibroblasts of patient A and her family members and used for cDNA synthesis and evaluation of IFNGR2 transcripts according to standard procedures. Primers are available on request. One hundred and fifty healthy controls of Chinese ethnicity were analyzed for the missense variant in IFNGR1 identified in patient B. Primers are available on request.
Immunologic analyses
Absolute lymphocyte counts were performed according to standard procedures (Trucount, BD Biosciences, San Jose, Calif). PBMCs were isolated by density gradient centrifugation (Lymphoprep, Axis-Shield, Dundee, United Kingdom) and maintained in complete medium (RPMI-1640 supplemented with 2 mM L-glutamine and 10% FBS; all Hyclone, South Logan, Utah). Intracellular expression of perforin was evaluated by using flow cytometry in both patients as previously described. E6 NK-cell and cytotoxic T lymphocytes degranulation was assessed by using flow cytometry as previously described. E7 NK-cell cytotoxicity against K562 target cells was evaluated in patient A with a standard 4-hour 51 Cr-release assay using PBMCs, as previously described. E8 To evaluate signal transducer and activator of transcription 1 signaling, PBMCs from patient A were thawed and stained, after overnight incubation, with fixable dead cell stain (Invitrogen, Carlsbad, Calif). PBMCs (1 3 10 6 ) were resuspended and either left untreated or stimulated with 500 U/mL IFN-a (PBL Interferon Source, Logan, Utah) or 100 ng/mL IFN-g (Peprotech, Rocky Hill, NJ) for 30 minutes. The cells were fixed, washed in PBS, and permeabilized for 30 minutes at 2208C (Perm Buffer III, BD Biosciences). The cells were thereafter stained with anti-CD14 and anti-signal transducer and activator of transcription 1 pY701 antibodies (both BD Biosciences). The cells were washed and analyzed by using flow cytometry (LSR Fortessa, BD Biosciences). Dead cells were excluded and monocytes identified by forward scatter and side scatter characteristics and CD14 staining. All analyses were performed using FlowJo software (v9.7.5; Tree Star, Ashland, Ore). IFN-g release assay was performed using the Quantiferon-TB Gold test (Qiagen, Hilden, Germany) following the manufacturer's instructions. Briefly, whole blood was incubated for 16 hours at 378C with mitogen (positive control), TB antigen, or nothing (negative control), respectively. Plasma IFN-g levels were then quantified using an ELISA plate. 
